127.82
127.82 (0%)
As of Feb 14, 2025
Intra-Cellular Therapies, Inc. [ITCI]
Source:
Company Overview
Intra-cellular Therapies, Inc is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | 212-923-3344 |
| Industry | manufacturing |
| CEO | Sharon Mates, Ph.D. |
| Website | www.intracellulartherapies.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $680.9 |
| Operating Profit | $-116.7 |
| Net Income | $-74.7 |
| Net Cash | $159.2 |
Profit Ratios
| Gross Margin | $623.9 |
| Operating Margin | -17.1 |
| Profit as % of Revenues | -835.5% |
| Profit as % of Assets | -7.1% |
| Profit as % of Stockholder Equity | -6.5% |
Management Effectiveness
| Return on Equity | -6.5% |
| Return on Assets | -5.5% |
| Turnover Ratio | 65% |
| EBITA | $-116.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,366.9 |
| Total Liabilities | $218.5 |
| Operating Cash Flow | $-73.2 |
| Investing Cash Flow | $-335.2 |
| Financing Cash Flow | $567.5 |
